01.10.2014 13:44:06
|
Isis Pharma Earns $1.5 Mln From GSK For The Advancement Of ISIS-GSK4 Rx
(RTTNews) - Isis Pharmaceuticals Inc. (ISIS) announced that it has earned a $1.5 million milestone payment from GSK related to the advancement of the program to develop ISIS-GSK4Rx to treat an undisclosed ocular disease.
"Our collaboration with GSK has been very productive resulting in four drugs in development. We look forward to advancing ISIS-GSK4Rx into clinical development and providing more information on the target and disease opportunity, which we are very excited about," said Lynne Parshall, chief operating officer at Isis.
![](https://images.finanzen.at/images/unsortiert/wertpapierdepot-absichern-aktienchart-boerse-750493204-260.jpg)
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu ISIS Pharmaceuticals Inc.mehr Nachrichten
Keine Nachrichten verfügbar. |